Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
ValenciaNOVEMBER201922ND
21ST
Chair
Dr. Mariano ProvencioHospital Univ. Puerta de Hierro, Majadahonda (Madrid)
13th
on
www.gecp.org/lungcancer2019
09:00 - 10:00 SESSION I: NSCLC. EARLY STAGES CURRENT MANAGEMENT
Chairs: Dr. José Luis González-Larriba Hospital Clínico San Carlos, Madrid
Dr. Teresa Morán ICO Badalona. Hospital Univ. German Trias i Pujol, Barcelona
09:00-09:15 Current treatment approaches in early diseases Dr. Bartomeu Massutí Hospital General Univ. de Alicante
09:15-09:30 Comorbidities: assessment tools and effect on outcome Dr. Jose Miguel Sánchez Hospital Univ. de la Princesa, Madrid
09:30-09:45 Primary prevention in Europe Prof. Enrica Capelletto University of Turin, Orbassano (Italy)
09:45-10:00 Discussion
10:00 - 11:00 MOLECULAR BOARD IN THE CLINICAL PRACTICE: SEPARATING FACTS FROM MYTHS
Chairs: Dr. Manuel Cobo Hospital Regional Univ. Carlos Haya, Málaga
Dr. Vanessa Ospina Hospital Univ. Fundación Santa Fe de Bogotá (Colombia)
10:00-10:15 Do you need it in your hospital? YES Dr. Manuel Cobo Hospital Regional Univ. Carlos Haya, Málaga
10:15-10:30 Do you need it in your hospital? NOT YET Dr. Jordi Remón Centro Integral Oncológico Clara Campal, Barcelona
10:30-10:45 Moving genomics to daily practice Dr. Bartomeu Massuti Hospital General Univ. de Alicante
10:45-11:00 Discussion
11:00-11:30 Coffee Break
Dr. Mariano ProvencioHospital Universitario Puerta de Hierro, Majadahonda, Madrid
Dr. Carlos CampsHospital General Univ. de Valencia
Dr. Bartomeu MassutíHospital General Univ. de Alicante
Dr. Alfredo SánchezHospital Provincial de Castellón
Dr. Ana BlascoHospital General. Univ. de Valencia
Dr. Oscar Juan-VidalHospital Univ. La Fe, Valencia
Dr. Natividad MartinezHospital General Univ. de Alicante
Dr. Amelia InsaHospital Clínico Univ. de Valencia
Dr. Maria GuiradoHospital General Univ. de Elche, Alicante
Dr. Mariano ProvencioHospital Universitario Puerta de Hierro, Majadahonda, Madrid
Dr. Carlos CampsHospital General Universitario, Valencia CIBERONC
Dr. Enric CarcerenyICO, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona
Dr. Bartomeu MassutíHospital General Universitario, Alicante
Dr. Ernest NadalICO, Hospital Durán i Reynals, L´Hospitalet de Llobregat, Barcelona
Dr. Manuel CoboHospital General Universitario Carlos Haya, Málaga
Dr. Ramón de las PeñasConsorcio Hospital Provincial, Castellón
Dr. Manuel DomineHopital Universitario Fundación Jiménez Díaz, Madrid
Dra. María Rosario García-CampeloHospital Teresa Herrera, A Coruña
Dr. Jose Luis Gonzalez LarribaHospital Clínico San Carlos, Madrid
Dra. Noemí ReguartHospital Clinic, Barcelona
Dra. Ivana Gabriela SullivanHospital Sant Pau, Barcelona
SCIENTIFIC COMMITEE
ORGANIZING COMMITEE
Thursday NOVEMBER201921ST
Thursday NOVEMBER201921ST
15:00 - 16:30 EDUCATIONAL SESSION: ADVANCES IN THE SURGICAL MANAGEMENT OF NSCLC
Chairs: Dr. Florentino Hernando-Trancho Hospital Clínico San Carlos, Madrid
Dr. Néstor Martínez Hospital de La Ribera, Alcira, Valencia
15:00-15:20 Lymphadenectomy and its implications. The SCAT trial Dr. José Ramón Jarabo Hospital Clínico San Carlos, Madrid
15:20-15:40 Lung cancer: SECT Multicenter working groups surgical results Dr. Sergi Call Hospital Univ. Mutua Terrassa, Barcelona
15:40-16:00 Quality criteria for the resection of thymic tumors and its registration Dr. Juan Carlos Trujillo Hospital Univ. de la Santa Creu i Sant Pau, Barcelona
16:00-16:30 Discussion
16:30 - 17:30 SESSION III: BIOLOGICAL PHENOMENA THAT INFLUENCES THE RESULTS
Chairs: Dr. Ivana Sullivan Hospital Univ. de la Santa Creu i Sant Pau, Barcelona
Dr. Luis Paz-Ares Hospital Univ. 12 de Octubre, Madrid
16:30-16:45 Heterogeneity, clonality and subclonality Dr. Nicholas McGranahan University College of London (UK)
16:45-17:00 NeoAntigenicity Dr. Rafael Sirera Universidad Politécnica de Valencia
17:00-17:15 Tumorstemcells.Keysinitsidentificationandtreatment Dr. Martin Barr Trinity College, Dublín (Ireland)
17:15-17:30 Discussion
17:30-18:00 Coffee Break
11:30 - 13:00 SESSION II: BIOLOGICAL FUNDAMENTALS FROM BASICS TO CLINICS
Chairs: Dr. Eloisa Jantus Hospital General Univ. de Valencia
Dr. Miguel A. Molina Hospital Univ. Quirón Dexeus, Barcelona
Dr. Atocha Romero Hospital Univ. Puerta de Hierro, Majadahonda, Madrid
11:30-11:45 Epigenetic biomarkers for cancer diagnosis Dr. Juan Sandoval Instituo de Investigación Sanitaria La Fe, Valencia
11:45-12:00 Early onset lung cancer Dr. Ernest Nadal ICO Hospitalet. Hospital Duran i Reynals, Barcelona
12:00-12:15 Emerging biomarkers in immune-oncology: Some insights from NADIM trial Dr. Alberto Cruz Hospital Univ. Puerta de Hierro, Majadahonda, Madrid
12:15-12:30 Liquid Biopsy: When sensitivity matters. Results from the RING study Dr. Atocha Romero Hospital Univ. Puerta de Hierro, Majadahonda, Madrid
12:30-12:45 New resistance mechanisms to EGFR-TKIs in NSCLC Dr. Jordi Bertran-Alamillo Hospital Univ. Quirón Dexeus, Barcelona
12:45-13:00 Discussion
13:00 - 13:30 CONFERENCE
Chair: Dr. Mariano Provencio Hospital Univ. Puerta de Hierro, Majadahonda, Madrid
DDR mechanisms and immunotherapy resistance Dr. Rafael Rosell Instituto de Investigación en Ciencias de la Salud Germans Trias i Pujol (IGTP) Badalona, Barcelona
13:30 - 15:00 SATELLITE LUNCH SYMPOSIUM Unique patients, unique approaches Sponsored by Roche
Terra meeting room (-1 floor)
18:00 - 18:45 SESSION IV: SUMMARY OF THE SLCG PROJECTS
Chairs: Dr. Alfredo Sánchez Hospital Provincial de Castellón
Dr. Joaquín Casal Complejo Hospitalario Univ. de Vigo
18:00-18:15 Earlystagesandfirstline: LINC/BR.31; NADIM; PEBEL, Atezo-BRAIN, TELMA, CHESS Dr. Ana Blasco Hospital General. Univ. de Valencia
18:15-18:30 Second line: DURVAST, BOOSTER, ALERT, REPLAY, THOMAS Dr. Joaquim Bosch ICOGirona.HospitalUniv. Dr.JosepTrueta,Girona
18:30-18:45 Other tumors and pharmacogenomic studies: STIMULI, Beat-MESO, Biopsia líquida, RING, SELINA Dr. Rafael López Hospital Clínico Univ. de Valladolid
18:45 - 19:30 SESSION V: OPTIMIZING TREATMENT IN STAGE III
Chairs: Dr. Amelia Insa Hospital Clínico Univ. de Valencia
Dr. Ana Laura Ortega Complejo Hospitalario de Jaén
18:45-19:00 Clinical-therapeuticsignificanceofthedifferent subtypes of stage III Dr. Maria Guirado Hospital General Univ. de Elche, Alicante
19:00-19:15 Integrating IO in treatment strategies Dr. Virginia Calvo Hospital Univ. Puerta de Hierro, Majadahonda, Madrid
19:15-19:30 Discussion
Friday NOVEMBER201922nd
08:00 - 09:00 PLENARY SESSION OF THE SLCG
09:00 - 10:00 SESSION VI: IMMUNE-CHECKPOINT INHIBITORS IN NSCLS: AS SINGLE AGENTS OR IN COMBINATION WITH CHEMOTHERAPY
Chairs: Dr. Antonio Araújo Centro Hospitalar do Porto (Portugal)
Dr. Remei Blanco Hospital de Terrassa, Barcelona
09:00-09:15 First line options for patients without oncogene driver Dr. Juan Coves Hospital Son Llàtzer, Palma de Mallorca
09:15-09:30 Rationale for combining treatments Dr. Ramón Palmero ICO Hospitalet. Hospital Duran i Reynals, Barcelona
09:30-09:45 Recommendations in the second line treatment using firstlinePDL1andTMBasapredictivebiomarker for immune-oncology therapy: Is there anything missing? Dr. Isidoro Barneto Hospital Univ. Reina Sofía, Córdoba
09:45-10:00 Discussion
10:00 - 11:00 PROFFERED PAPER SESSION
Chairs: Dr. Oscar Juan-Vidal Hospital Univ. La Fe, Valencia
Dr. María González Cao Hospital Univ. Dexeus, Barcelona
POSTER PRESENTATIONS & AWARDS Sponsored by Roche
Poster 18 Anti-egf antibodies increase the effect of alk and mek inhibitors in alk and kras nsclc cell lines
Poster 28 Osimertinib vs comparator egfr-tki as first-line treatment for egfrm advanced nsclc (flaura): final overall survival analysis
Poster 34 Functional systemic cd4 immunity is required for clinical responses to pd-l1/pd-1 blockade therapy in lung cancer
Poster 37 Lung tumorspheres reveal cancer stem cell properties, potential targets and a prognostic score for non-small cell lung cancer
Poster 49 Niveles basales de células supresoras mieloides inmaduras circulantes como marcadores predictivos de eficacia a inmunoterapia anti-pd1/pd-l1 en cáncer de pulmón no microcítico avanzado
Poster 50 A 770 gene panel expression analysis to predict clinical benefit of durvalumab in hiv-infected cancer patients
Friday NOVEMBER201922nd
13:30 - 14:15 SESSION IX: BIOLOGICAL CONCEPTS SURROUNDING RESISTANCE IN THE TREATMENT OF LUNG CANCER
Chairs: Dr. Reyes Bernabé Hospital Univ. Virgen del Rocío, Sevilla
Dr. Javier de Castro Hospital Univ. La Paz, Madrid
13:30-13:45 Biological basis of resistance mechanisms in oncogenic drivers Dr. Natividad Martínez Hospital General Univ. de Alicante
13:45-14:00 Biological basis resistance mechanisms in immunotherapy Dr. Santiago Viteri Hospital Univ. Quirón Dexeus, Barcelona
14:00-14:15 Discussion
14:15 - 15:15 SESSION X: SCLC NEW OPPORTUNITIES
Chair: Dr. Claudio Martín Instituto Alexander Fleming, Buenos Aires, Argentina
Dr. Manuel Dómine Hospital Univ. Fundación Jiménez Díaz, Madrid
14:15-14:30 Genomics of SCLC: Relevant advances Dr. Noemi Reguart Hospital Clinic de Barcelona
14:30-14:45 Immunotherapy in SCLC Dr. Antonio Calles Hospital General Univ. Gregorio Marañón, Madrid
14:45-15:00 New drugs Dr. Dolores Isla Hospital Clínico Univ. Lozano Blesa, Zaragoza
15:00-15:15 Discussion
15:15-15:20 Closing remarks
11:00 - 11:45 SESSION VII: REAL WORLD DATA IN LUNG CANCER
Chair: Dr. Carlos Carracedo ALIADAS, Instituto Nacional de Enfermedades Neoplásicas, Lima (Perú)
Dr. Sergio Vázquez Hospital Univ. Lucus Augusti, Lugo
11:00-11:15 The role of the SLCG tumors registry Dr. Mariano Provencio Hospital Univ. Puerta de Hierro, Majadahonda, Madrid
11:15-11:30 Implementing personalized care. The french experience Dr. Benjamin Besse Institut Gustave Roussy, Villejuif (France)
11:30-11:45 Discussion
11:45-12:30 Coffee Break
12:30 - 13:30 SESSION VIII: NSCLC STAGE IV TREATMENT IN ONCOGENIC ADDICTED DISEASE
Chairs: Dr. Carlos Camps Hospital General Univ. de Valencia
Dr. Mª Angeles Sala Hospital de Basurto, Bilbao
12:30-12:45 Treatment algorithms for EGFR mutated patients Dr. Rosario García-Campelo Hospital Univ. de A coruña
12:45-13:00 How to organize the treatment in ALK /ROS1+ patients Dr. Enric Carcereny ICO Badalona. Hospital Univ. Germans Trias i Pujol, Barcelona
13:00-13:15 Targeted therapy beyond EGFR-ALK-ROS1 Dr. Margarita Majem Hospital Univ. de la Santa Creu I Sant Pau, Barcelona
13:15-13:30 Discussion
Round table: Redefining survival expectation for patients in 1st line mNSCLC wildtype
Terra meeting room (-1 floor)
Sponsored by MSD
Platinum
Silver
Bronze
Other Collaborations
Supporting Companies
This activity has been recognized as of scientific interest by the Health and Social Services Ministry.
Activitat acreditada pel Consell Català de la Formació Continuada de les Professions Sanitàries (CCFCPS) - Comisión de Formación Continuada del Sistema Nacional de Salud con 1,5 CRÉDITOS, expedient núm.: 09/025931-MD.
It is mandatory to attend the 100% of the congress plenary sessions to obtain the certificate of attendance with credits. Please do not forget to scan your badge at the entrance of the meeting room everyday.
General Information
Under the Auspices of
Credits
ScientificInterest
Venue
Hotel Meliá ValenciaAv. de Les Corts Valencianes 5246015 Valencia
Holding a badge will be required to access the meeting room.
Conference Secretariat
Language
Lectures will be delivered in English or Spanish.
Monasterios de Suso y Yuso 34 · 28049 Madrid (+34) 91 372 02 03 e-mail: [email protected]/lungcancer2019